Integrated analysis of Dendrobium nobile extract Dendrobin A against pancreatic ductal adenocarcinoma based on network pharmacology, bioinformatics, and validation experiments

• Published in: Frontiers in pharmacology Vol. 14; p. 1079539
• Main Authors: Xu, Xiaoqing, Yu, Yaping, Yang, Li, Wang, Bingshu, Fan, Yonghao, Ruan, Banzhan, Zhang, Xiaodian, Dai, Haofu, Mei, Wenli, Jie, Wei, Zheng, Shaojiang
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 01.03.2023
• Subjects: bioinformatics; Dendrobin A; Dendrobium nobile; network pharmacology; pancreatic ductal adenocarcinoma; Pharmacology; PLAU; Dendrobium nobile; Dendrobin A; PLAU; network pharmacology; bioinformatics; pancreatic ductal adenocarcinoma
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2023.1079539

( ), a traditional Chinese medicine, has received attention as an anti-tumor drug, but its mechanism is still unclear. In this study, we applied network pharmacology, bioinformatics, and experiments to explore the effect and mechanism of Dendrobin A, the active ingredient of , against pancreatic ductal adenocarcinoma (PDAC). The databases of SwissTargetPrediction and PharmMapper were used to obtain the potential targets of Dendrobin A, and the differentially expressed genes (DEGs) between PDAC and normal pancreatic tissues were obtained from The Cancer Genome Atlas and Genotype-Tissue Expression databases. The protein-protein interaction (PPI) network for Dendrobin A anti-PDAC targets was constructed based on the STRING database. Molecular docking was used to assess Dendrobin A anti-PDAC targets. PLAU, one of the key targets of Dendrobin A anti-PDAC, was immunohistochemically stained in clinical tissue arrays. Finally, experiments were used to validate the effects of Dendrobin A on PLAU expression and the proliferation, apoptosis, cell cycle, migration, and invasion of PDAC cells. A total of 90 genes for Dendrobin A anti-PDAC were screened, and a PPI network for Dendrobin A anti-PDAC targets was constructed. Notably, a scale-free module with 19 genes in the PPI indicated that the PPI is highly credible. Among these 19 genes, PLAU was positively correlated with the cachexia status while negatively correlated with the overall survival of PDAC patients. Through molecular docking, Dendrobin A was found to bind to PLAU, and the Dendrobin A treatment led to an attenuated PLAU expression in PDAC cells. Based on clinical tissue arrays, PLAU protein was highly expressed in PDAC cells compared to normal controls, and PLAU protein levels were associated with the differentiation and lymph node metastatic status of PDAC. experiments further showed that Dendrobin A treatment significantly inhibited the proliferation, migration, and invasion, inducing apoptosis and arresting the cell cycle of PDAC cells at the G2/M phase. Dendrobin A, a representative active ingredient of , can effectively fight against PDAC by targeting PLAU. Our results provide the foundation for future PDAC treatment based on .